Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carboplatin-Paclitaxel · 1 trial · 1 indication
Defined as the time from the date of randomization until objective tumor progression based on RECIST 1.1, by BICR (Blinded Independent Central Review), or death due to any cause, whichever occurs first. Patients alive and free of progression will be censored at the last disease assessment date.
| Arm | Type | Description |
|---|---|---|
| Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks | EXPERIMENTAL | - |
| Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles. | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Carboplatin-Paclitaxel | DRUG | Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles |
| Dostarlimab | DRUG | Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years. |
Inclusion Criteria: * Patients must fulfil all the following criteria: 1. Female patient is at least 18 years of age, 2. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements. 3. Patient with histologically proven endometrial adenocarcinoma with recur...
Top 20 of 52 competitors